Skip to contentW
West Pharmaceutical Services Inc
W
WSTWest Pharmaceutical Services Inc Q2 2019 · 10-Q
Revenue$469.70M$469.70M+5.0% vs Q2 2018 Net Income$66.10M$66.10M+17.8% vs Q2 2018 EPS Diluted$0.88$0.88+17.3% vs Q2 2018 Gross Profit$157,900,000+11.0% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
West Pharmaceutical Services Inc · CIK 105770 · Engraved from SEC EDGAR
Operating Cash Flowderived$105,100,000+28.2% Free Cash Flowderived$76,800,000+24.3% Margins · derivedGross margin33.6%+1.8 pt vs Q2 2018
Operating margin17.1%+3.7 pt vs Q2 2018
Net margin14.1%+1.5 pt vs Q2 2018
ended Jun 30, 2019 · filed Jul 29, 2019 · 29 d after period end